Search

Author/Creator Behrens, F.

31. OP0050 ADALIMUMAB INTRODUCTION VERSUS METHOTREXATE DOSE ESCALATION IN PATIENTS WITH INADEQUATELY CONTROLLED PSORIATIC ARTHRITIS: RESULTS FROM RANDOMIZED PHASE 4 CONTROL STUDY. (2nd June 2020)

Authors:
Coates, L. C.; Tillett, W.; D'agostino, M. A.; Rahman, P.; Behrens, F.; Conaghan, P. G.; Mcdearmon-Blondell, E.; Bu, X.; Chen, L.; Kapoor, M.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
33
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

32. OP0117 LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL. (2nd June 2020)

Authors:
Rech, J.; Tascilar, K.; Schenker, H.; Hagen, M.; Sergeeva, M.; Selvakumar, M.; Konerth, L.; Prade, J.; Strobelt, S.; Schönau, V.; Valor, L.; Hueber, A.; Simon, D.; Kleyer, A.; Behrens, F.; Baerwald, C.; Finzel, S.; Voll, R.; Feist, E.; Da Silva, J. A. P.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
77
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

33. OP0128 PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. (9th June 2015)

Authors:
Budu-Aggrey, A.; Lohr, S.; Bowes, J.; Uebe, S.; Bruce, I.N.; Feletar, M.; Marzo-Ortega, H.; Helliwell, P.; Ryan, A.W.; Kane, D.; Korendowych, E.; Alenius, G.-M.; Giardina, E.; Packham, J.; McManus, R.; FitzGerald, O.; McHugh, N.; Brown, M.A.; Behrens, F.; Burkhardt, H.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
116
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

34. OP0218 CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL. (2nd June 2020)

Authors:
Schenker, H.; Rech, J.; Tascilar, K.; Hagen, M.; Schönau, V.; Sergeeva, M.; Selvakumar, M.; Konerth, L.; Prade, J.; Strobelt, S.; Valor, L.; Hueber, A.; Simon, D.; Kleyer, A.; Behrens, F.; Da Silva, J. A. P.; Baerwald, C.; Finzel, S.; Voll, R.; Feist, E.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

35. OP0225 TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE. (2nd June 2020)

Authors:
Nash, P.; Coates, L. C.; Mease, P. J.; Kivitz, A.; Gladman, D. D.; Behrens, F.; Wei, J. C. C.; Fleishaker, D.; Wu, J.; Wang, C.; Romero, A. B.; Fallon, L.; Hsu, M. A.; Kanik, K.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
140
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

36. OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY. (2nd June 2020)

Authors:
Mcinnes, I.; Behrens, F.; Mease, P. J.; Kavanaugh, A.; Ritchlin, C. T.; Nash, P.; Gratacos-Masmitja, J.; Goupille, P.; Korotaeva, T.; Gottlieb, A. B.; Martin, R.; Ding, K.; Pellet, P.; Mpofu, S.; Pricop, L.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
142
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

37. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. (12th June 2018)

Authors:
Mease, P.J.; Kellner, H.; Morita, A.; Kivitz, A.J.; Papp, K.A.; Aslanyan, S.; Berner, B.; Chen, S.; Eldred, A.; Behrens, F.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
200
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

38. SAT0011 Replication of A Distinct Psoriatic Arthritis Risk Variant at IL23R. (15th July 2016)

Authors:
Budu-Aggrey, A.; Bowes, J.; Lohr, S.; Uebe, S.; Zervou, M.I.; Helliwell, P.; Ryan, A.W.; Kane, D.; Korendowych, E.; Giardina, E.; Packham, J.; McManus, R.; FitzGerald, O.; McHugh, N.; Behrens, F.; Burkhardt, H.; Huffmeier, U.; Ho, P.; Martin, J.; Castañeda, S.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
667
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

39. SAT0032 INCIDENCE OF RHEUMATOID ARTHRITIS IN PATIENTS WITH NEW ONSET OF MUSCULOSKELETAL SYMPTOMS AND ANTI-CPP POSITIVITY COMPARED TO ANTI-CPP NEGATIVE PATIENTS. (2nd June 2020)

Authors:
Dauth, S.; Köhm, M.; Oberwahrenbrock, T.; Henkemeier, U.; Rossmanith, T.; Mergenthal, K.; Petersen, J. J.; Burkhardt, H.; Behrens, F.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
946
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

40. SAT0050 PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA). (2nd June 2020)

Authors:
Rech, J.; Tascilar, K.; Schenker, H.; Sergeeva, M.; Selvakumar, M.; Konerth, L.; Prade, J.; Strobelt, S.; Hagen, M.; Schönau, V.; Valor, L.; Hueber, A.; Simon, D.; Kleyer, A.; Behrens, F.; Da Silva, J. A. P.; Baerwald, C.; Finzel, S.; Voll, R.; Feist, E.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
956
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗